Haemonetics Corporation
HAEHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHaemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. Valued at $4.68B, HAE is a mid-cap name in its sector. The company operates through Plasma, Blood Center, and Hospital segments.
Market Cap
$4.68B
Beta
0.54
P/E (TTM)
49.68
P/E (Fwd)
17.92
EPS (TTM)
$2.07
EPS (Fwd)
$5.74
ROE
11.2%
ROA
6.6%
Cash
$224.5M
Total Debt
$1.17B
Free CF
$312.8M
52W Change
91.8%
Annual Financials
Cash vs Debt
Where HAE stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, HAE finished 46.34% above its 150-day moving average ($70.33) and 42.15% above its 200-day moving average ($72.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HAE overbought or oversold?
At the September 3, 2026 close, HAE's RSI(14) was 72.7, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, HAE has $224.5M in cash with $1.17B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $312.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 11.2% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $1.17B to $1.33B.
With a beta below 0.7, Haemonetics Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Haemonetics Corporation and its sector.